ERBB2 and breast cancer: For breast cancer, further exploratory analyses by ER, PR and HER receptor status and by age at tumor diagnosis showed significant associations of HbA1c especially with risk of Her2 + cancers (p-heterogeneity = 0.04), and of tumors diagnosed after age 55, although no significant heterogeneity was observed (Supplemental Table S2).